129 related articles for article (PubMed ID: 10206071)
61. Protein kinase A-Ialpha subunit-directed antisense inhibition of ovarian cancer cell growth: crosstalk with tyrosine kinase signaling pathway.
Alper O; Hacker NF; Cho-Chung YS
Oncogene; 1999 Sep; 18(35):4999-5004. PubMed ID: 10490835
[TBL] [Abstract][Full Text] [Related]
62. Downmodulation of TGF-alpha protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells.
Grandis JR; Chakraborty A; Zeng Q; Melhem MF; Tweardy DJ
J Cell Biochem; 1998 Apr; 69(1):55-62. PubMed ID: 9513046
[TBL] [Abstract][Full Text] [Related]
63. Elucidation of gene function using C-5 propyne antisense oligonucleotides.
Flanagan WM; Su LL; Wagner RW
Nat Biotechnol; 1996 Sep; 14(9):1139-45. PubMed ID: 9631067
[TBL] [Abstract][Full Text] [Related]
64. Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck.
Thomas SM; Ogagan MJ; Freilino ML; Strychor S; Walsh DR; Gooding WE; Grandis JR; Zamboni WC
Mol Pharmacol; 2008 Mar; 73(3):627-38. PubMed ID: 18025070
[TBL] [Abstract][Full Text] [Related]
65. Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells.
Spänkuch-Schmitt B; Wolf G; Solbach C; Loibl S; Knecht R; Stegmüller M; von Minckwitz G; Kaufmann M; Strebhardt K
Oncogene; 2002 May; 21(20):3162-71. PubMed ID: 12082631
[TBL] [Abstract][Full Text] [Related]
66. Epidermal growth factor receptor (EGFR) antisense transfection reduces the expression of EGFR and suppresses the malignant phenotype of a human ovarian cancer cell line.
Brader KR; Wolf JK; Chakrabarty S; Price JE
Oncol Rep; 1998; 5(5):1269-74. PubMed ID: 9683849
[TBL] [Abstract][Full Text] [Related]
67. Expression of epidermal growth factor receptor and human papillomavirus E6/E7 proteins in cervical carcinoma cells.
Hu G; Liu W; Mendelsohn J; Ellis LM; Radinsky R; Andreeff M; Deisseroth AB
J Natl Cancer Inst; 1997 Sep; 89(17):1271-6. PubMed ID: 9293917
[TBL] [Abstract][Full Text] [Related]
68. Growth inhibition of breast cancer cells by Grb2 downregulation is correlated with inactivation of mitogen-activated protein kinase in EGFR, but not in ErbB2, cells.
Tari AM; Hung MC; Li K; Lopez-Berestein G
Oncogene; 1999 Feb; 18(6):1325-32. PubMed ID: 10022814
[TBL] [Abstract][Full Text] [Related]
69. Autocrine effects of transforming growth factor-alpha on the development of preimplantation mouse embryos.
Onohara Y; Harada T; Tanikawa M; Iwabe T; Yoshioka H; Taniguchi F; Mitsunari M; Tsudo T; Terakawa N
J Assist Reprod Genet; 1998 Jul; 15(6):395-402. PubMed ID: 9673886
[TBL] [Abstract][Full Text] [Related]
70. Triplex-forming oligonucleotide binding represses transcription of the human c-erbB gene in glioma.
Okada T; Yamaguchi K; Yamashita J
Growth Factors; 1994; 11(4):259-70. PubMed ID: 7779405
[TBL] [Abstract][Full Text] [Related]
71. Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas.
Walker RA; Dearing SJ
Breast Cancer Res Treat; 1999 Jan; 53(2):167-76. PubMed ID: 10326794
[TBL] [Abstract][Full Text] [Related]
72. An antisense oligodeoxynucleotide that depletes RI alpha subunit of cyclic AMP-dependent protein kinase induces growth inhibition in human cancer cells.
Yokozaki H; Budillon A; Tortora G; Meissner S; Beaucage SL; Miki K; Cho-Chung YS
Cancer Res; 1993 Feb; 53(4):868-72. PubMed ID: 8428367
[TBL] [Abstract][Full Text] [Related]
73. Inhibitory effect of 2'-o-methoxyethyl-modified antisense oligonucleotides targeting vascular endothelial growth factor A on SKOV3 human ovarian cancer cells.
Fu YB; Wen ZQ; Zhao XB; Yan L; Zhang CH; Wang F
Chin Med J (Engl); 2011 May; 124(10):1573-5. PubMed ID: 21740819
[TBL] [Abstract][Full Text] [Related]
74. A combination treatment of c-myc antisense DNA with all-trans-retinoic acid inhibits cell proliferation by downregulating c-myc expression in small cell lung cancer.
Akie K; Dosaka-Akita H; Murakami A; Kawakami Y
Antisense Nucleic Acid Drug Dev; 2000 Aug; 10(4):243-9. PubMed ID: 10984118
[TBL] [Abstract][Full Text] [Related]
75. Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and and in mice.
Leonetti C; D'Agnano I; Lozupone F; Valentini A; Geiser T; Zon G; Calabretta B; Citro G C; Zupi G
J Natl Cancer Inst; 1996 Apr; 88(7):419-29. PubMed ID: 8618233
[TBL] [Abstract][Full Text] [Related]
76. Manipulation of iron transporter genes results in the suppression of human and mouse mammary adenocarcinomas.
Jiang XP; Elliott RL; Head JF
Anticancer Res; 2010 Mar; 30(3):759-65. PubMed ID: 20392994
[TBL] [Abstract][Full Text] [Related]
77. Abrogation of VEGF expression in human head and neck squamous cell carcinoma decreases angiogenic activity in vitro and in vivo.
Riedel F; Götte K; Li M; Hörmann K; Grandis JR
Int J Oncol; 2003 Sep; 23(3):577-83. PubMed ID: 12888890
[TBL] [Abstract][Full Text] [Related]
78. Nanoparticle formulation enhances the delivery and activity of a vascular endothelial growth factor antisense oligonucleotide in human retinal pigment epithelial cells.
Aukunuru JV; Ayalasomayajula SP; Kompella UB
J Pharm Pharmacol; 2003 Sep; 55(9):1199-206. PubMed ID: 14604462
[TBL] [Abstract][Full Text] [Related]
79. EGF and TGF-alpha, the ligands of hyperproduced EGFR in human esophageal carcinoma cells, act as autocrine growth factors.
Yoshida K; Kyo E; Tsuda T; Tsujino T; Ito M; Niimoto M; Tahara E
Int J Cancer; 1990 Jan; 45(1):131-5. PubMed ID: 2298497
[TBL] [Abstract][Full Text] [Related]
80. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression.
Thompson ME; Jensen RA; Obermiller PS; Page DL; Holt JT
Nat Genet; 1995 Apr; 9(4):444-50. PubMed ID: 7795653
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
